Bayesian Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Bayesian Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-42,000	Closed	-$31K	–	808
2024 Q4	$31K	Buy	+42,000	New	+$50.6K	﹤0.01%	643
2024 Q1	–	Sell	-32,119	Closed	-$49.1K	–	971
2023 Q4	$49.1K	Buy	+32,119	New	+$38.2K	0.01%	678
2021 Q1	–	Sell	-16,300	Closed	-$56K	–	630
2020 Q4	$56K	Buy	+16,300	New	+$31.1K	0.01%	425
2016 Q1	–	Sell	-11,700	Closed	-$156K	–	400
2015 Q4	$156K	Buy	+11,700	New	+$144K	0.22%	196

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bayesian Capital Management's LXRX Position: Q1 2025 in Review

Bayesian Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2025, closing a stake of 42,000 shares — an estimated $31K sold.

Bayesian Capital Management first reported a position in LXRX in Q4 2015 and held it in 4 quarters. The position peaked at $156K in Q4 2015. 127 funds tracked by Wall St. Rank hold LXRX as of Q1 2025.

Bayesian Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Bayesian Capital Management sold 42,000 Lexicon Pharmaceuticals shares in Q1 2025, an estimated $31K.
Bayesian Capital Management first reported a position in Lexicon Pharmaceuticals in Q4 2015 and held it in 4 quarters.
Bayesian Capital Management's Lexicon Pharmaceuticals position peaked at $156K in Q4 2015.
127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2025.

Based on Bayesian Capital Management's 13F filing for Q1 2025, filed 15 May 2025.